Ortiz de Montellano Paul R.(Ed.) Cytochrome P450. Structure, Mechanism, and Biochemistry
Подождите немного. Документ загружается.
Human and
Rat
Liver Cytochromes P450
647
1.
Estimation
of
Cytochrome
P420
in
Cytochrome P450
Preparations
Using the spectral baseline correction mode,
determine the peak spectral absorption differ-
ences (AA) between 420-490 nm (P420) and
450-490 nm (P450) of CO-reduced-reduced
(Fe+2C0-Fe+2) samples226,227,233,245
[P450]:
AA45(^9o^/0.091=X nmol/ml (with
emM'^cm"^ = 91)
[P420]:
AA42o^9o„^
^^-^^^
= ^ nmol/ml (with
emM-^cm-i = 110)
(~0.041)X nmol/ml = correction for negative
contribution of P450 to P420 peak absorption at
-420-424 nm(emM-icm-i = -41)
Actual [P420] in P450 preparations:
7-[(-0.041X)/0.110] = Z nmol/ml
2.
Determination
of
Cytochrome
P450 Reductase Activity
Carried out with NADPH as the electron donor
and cytochrome c as the artificial electron
acceptor by the method of Philips & Langdon^"*^
as detailed245-247
Using the AA^^Q^Jmin and an EmM~^cm~^
= 21 determine [AA55Qjjjjj/min]/0.021 = X nmol
cytochrome c reduced/min^"^^"^"^^.
Purified liver P450 reductase preparations
range from 40-70 ixmol c3^oclirome c reduced/
mg protein/min. Molar concentrations of purified
P450 reductase are estimated using either a
molecular weight of 74kDa (based on cDNA
sequence as well as flavin and protein content)
or an apparent molecular weight of 79.5 kDa
(SDS-PAGE).
Aclcnowledgments
Supported by NIH grants DK26506 and
GM44037.
References
1.
Sato,
R. and T.
Omura
(eds)
(1978). Cytochrome
P450. Academic Press, New
York,
NY.
2.
Sato,
R.,
T. Omura,
Y
Imai, and
Y.
Fujii-Kuriyama
(eds) (1987). Cytochrome P450:
New
trends.
Yamada Science Foundation, Japan.
3.
Estabrook,
R.W. and M.E.
Pullman
(eds)
(1967).
Methods
in
Enzymology
Volume
10: Oxidation and
Phosphorylation. Academic Press, New York, NY.
4.
Fleischer, S. and L. Packer (eds) (1978). Methods
in
Enzymology, Volume
52:
Biological Oxidations,
Microsomal cytochrome P450,
and
other hemopro-
tein systems. Academic Press, New York, NY.
5.
Johnson,
E.F. and M.R.
Waterman
(eds)
(1991).
Methods
in
Enzymology, Volume 206: Cytochrome
P450, Part
A.
Academic Press, New York, NY.
6. Johnson,
E.R and M.R.
Waterman
(eds)
(1996).
Methods
in
Enzymology, Volume 272: Cytochrome
P450, Part B. Academic Press, New
York,
NY.
7.
Johnson,
E.R and M.R.
Waterman
(eds)
(2002).
Methods
in
Enzymology, Volume 357: Cytochrome
P450, Part C. Academic Press, New York, NY.
8. Phillips,
I.R. and E.A.
Shephard
(eds)
(1998).
Methods
in
Molecular Biology, Volume
107:
Cytochrome P450 Protocols.
9. Testa,
B. and R
Jenner
(eds)
(1976). Drug
Metabolism: Chemical
and
Biological Aspects.
Marcel Dekker.
10.
Ortiz
de
Montellano,
PR.
(ed.) (1986). Cytochrome
P450: Structure, Mechanism
and
Biochemistry.
Plenum Press, New York, NY.
11.
Guengerich,
F.P. (ed.)
(1987). Mammalian
Cytochromes P450, Vols
1 & 2, CRC
Press, Boca
Raton,
FL.
12.
Schenkman,
J.B. and D.
Kupfer
(eds)
(1982).
Hepatic Cytochrome P450 Monooxygenase System.
Pergamon Press, Elmsford, NY.
13.
Ortiz
de
Montellano, PR. (ed.) (1995). Cytochrome
P450: Structure, Mechanism
and
Biochemistry.
Plenum Press, New York, NY.
14.
Waxman,
D.J.
(1986).
Rat
hepatic cytochrome
P-450: Comparative study
of
multiple isozymic
forms.
In
PR. Ortiz de Montellano (ed.). Cytochrome
P-450. Structure, Mechanism,
and
Biochemistry.
Plenum Press, New
York,
NY, pp. 525-538.
15.
Gonzalez,
F.J.
(1989).
The
molecular biology
of
cytochrome P450s. Pharmacol. Rev. 40, 243-288.
16.
Guengerich,
F.P.
(2002). Update information
on
human P450s. Drug
Metab.
Rev. 34, 7-15.
17.
Wrighton,
S.A., M.
VandenBranden,
J.C.
Stevens,
L.A. Shipley, and B.J. Ring (1993). In vitro methods
for assessing human hepatic drug metabolism: Their
use
in
drug development. Drug Metab.
Rev. 25,
453^84.
18.
Newton,
D.J., R.W.
Wang,
and A.Y Lu
(1995).
Cytochrome P450 inhibitors. Evaluation
of
speci-
ficities
in the in
vitro metabolism
of
therapeutic
agents
by
human liver microsomes, Drug Metab.
Dispos. 23, 154-158.
648
M.A. Correia
19.
Nelson, D.R., L. Koymans, T. Kamataki,
J.J. Stegeman, R. Feyereisen, D.J. Waxman et al.
(1996).
P450 superfamily: Update on new
sequences, gene mapping, accession numbers and
nomenclature. Pharmacogenetics 6, \-A2.
20.
Guengerich, F.R (1995). Human cytochrome P450
enzymes. In RR. Ortiz de Montellano (ed.),
Cytochrome P450: Structure, Mechanism and
Biochemistry. Plenum Press, New York, NY,
pp.
473-574.
21.
Guengerich, F.R (2004). Human cytochrome P450
enzymes. In, PR. Ortiz de Montellano (ed.). Cyto-
chrome P450: Structure, Mechanism and Bio-
chemistry. Plenum
Press,
New
York,
NY,
pp.
370-530.
22.
Rendic, S. and RJ. Di Carlo (1997). Human
C5^ochrome P450 enzymes: A status report summa-
rizing their reactions, substrates, inducers, and
inhibitors. Drug
Metab.
Rev. 29, 413-580.
23.
Rendic, S. (2002). Summary of information on
human CYP enzymes: Human P450 metabolism
data. Drug
Metab.
Rev. 34, 83-448.
24.
Kobayashi, K., K. Urashima, N. Shimada, and
K. Chiba (2003). Selectivities of human cytochrome
P450 inhibitors toward rat P450 isoforms: Study
with cDNA-expressed systems of the rat. Drug
Metab. Dispos. 31, 833-836.
25.
Kobayashi, K., K. Urashima, N. Shimada, and
K. Chiba (2002). Substrate specificity for rat
cytochrome P450 (CYP) isoforms: Screening with
cDNA-expressed systems of the rat. Biochem.
Pharmacol 63, 889-896.
26.
Yuan, R., S. Madani, X.X. Wei, K. Reynolds, and
S.M. Huang (2002). Evaluation of cytochrome P450
probe substrates commonly used by the
pharmaceutical industry to study in vitro drug inter-
actions. Drug
Metab.
Dispos. 30, 1311-1319.
27.
Eagling, VA., J.R Tjia, and D.J. Back (1998).
Differential selectivity of cytochrome P450 inhi-
bitors against probe substrates in human and rat
liver microsomes. Br J. Clin. Pharmacol. 45,
107-114.
28.
Fuhr, U, J. Doehmer, N. Battula, C. Wolfel,
C. Kudla,
Y.
Keita et al. (1992). Biotransformation
of caffeine and theophylline in mammalian cell
lines genetically engineered for expression of single
cytochrome P450 isoforms. Biochem. Pharmacol.
43,
225-235.
29.
Tassaneeyakul, W., Z. Mohamed, D.J. Birkett, M.E.
McManus, M.E. Verones, R.H. Tukey et al. (1992).
Caffeine as a probe for human cytochromes P450:
Validation using cDNA expression, immuno-
inhibition and microsomal kinetic and inhibitor
techniques. Pharmacogenetics 2, 173-183.
30.
Tassaneeyakul, W., D.J. Birkett, M.E. Veronese,
M.E. McManus, R.H. Tukey, L.C. Quattrochi et al.
(1993).
Specificity of substrate and inhibitor
probes for human cytochromes P450 lAl and 1A2.
J. Pharmacol. Exp. Ther 265, 401-407.
31.
Sesardic, D, A. Boobis, B. Murray, S. Murray,
J. Segura, R. De La Torre et
al.
(1990). Furafylline is
a potent and selective inhibitor of cytochrome P450
1A2 in man. Br J. Clin. Pharmacol. 29, 651-663.
32.
Kunze, K.L. and W.F Trager (1993). Isoform-
selective mechanism-based inhibition of human
cytochrome P450 1A2 by fiirafylline. Chem. Res.
Toxicol.
6, 649-656.
33.
Clarke, S.E., A.D. Ayrton, and R.J. Chenery (1994).
Characterization of the inhibition of P4501A2 by
furafylline. Xenobiotica 24, 517-526.
34.
Tjia, J.R, J. Colbert, and D.J. Back (1996).
Theophylline metabolism in human liver micro-
somes: Inhibition studies. J. Pharmacol. Exp. Ther
276,912-917.
35.
Butler, M.N., M. Iwasaki, F.R Guengerich, and
F.K. Kadlubar (1989). Human cytochrome
P-450PIA (P450IA2), the phenacetin 0-deethylase,
is primarily responsible for the hepatic 3-
demethylation of caffeine and N-oxidation of car-
cinogenic arylamines, Proc. Natl.
Acad.
Sci. USA,
86,
7696-7700.
36.
Yun, C.H., G.R Miller, and FP Guengerich (2000).
Rate-determining steps in phenacetin oxidations by
human cytochrome P450 1A2 and selected
mutants. Biochemistry 39, 11319-11329.
37.
Yang, TJ., Y Sai, K.W. Krausz, FJ. Gonzalez, and
H.V Gelboin (1998). Inhibitory monoclonal
antibodies to human cytochrome P450 1A2:
Analysis of phenacetin 0-deethylation in human
liver. Pharmacogenetics 8, 375-382.
38.
Zhai, S., R. Dai, FK. Friedman, and R.E. Vestal
(1998).
Comparative inhibition of human
cytochrome P450 lAl and 1A2 by flavonoids.
Drug
Metab.
Dispos. 26, 989-992.
39.
Lee, H., H. Yeom, YG. Kim, C.N. Yoon, C. Jin,
J.S.
Choi et al. (1998). Structure-related inhibition
of human hepatic caffeine N3-demethylation by
naturally occurring flavonoids.
Biochem.
Pharmacol.
55,
1369-1375.
40.
Burke, M.D., S. Thompson, R.J. Weaver, C.R.
Wolf,
and R.T. Mayer (1994). Cytochrome P450 speci-
ficities of alkoxyresorufin 0-dealkylation in human
and rat liver. Biochem. Pharmacol. 48, 923-936.
41.
Rodrigues,
A.D.
and R.A. Prough (1992). Induction
of cytochromes P450IA1 and P450IA2 and
measurement of catalytic activities. Meth. Enzymol.
206,423^31.
43.
Yun, C.H., T Shimada, and FR Guengerich (1991).
Purification and characterization of human liver
microsomal cytochrome P-450 2A6. Mol.
Pharmacol. 40, 679-685.
44.
Yamano, S., J. Tatsuno, and FJ. Gonzalez (1990).
The CYP2A3 gene product catalyzes coumarin
Human and Rat Liver Cytochromes P450
649
7-hydroxylation in human liver microsomes.
Biochemistry 19, 1322-1329.
45.
Sai, Y., T.J. Yang, K.W. Krausz, F.J. Gonzalez, and
H.V Gelboin (1999). An inhibitory monoclonal
antibody to human cytochrome P450 2A6 defines
its role in the metabolism of coumarin, 7-
ethoxycoumarin and 4-nitroanisole in human liver.
Pharmacogenetics 9, 229-237.
46.
Zhang, W., T. Kilicarslan, R.F. Tyndale, and
E.M. Sellers (2001). Evaluation of methoxsalen,
tranylcypromine, and trj^tamine as specific and
selective CYP2A6 inhibitors in vitro. Drug Metab.
Dispos. 29, 897-902
47.
Taavitsainen, P., R. Juvonen, and O. Pelkonen
(2001).
In vitro inhibition of cytochrome P450
enzymes in human liver microsomes by a potent
CYP2A6 inhibitor, trans-2-phenylcyclopropylamine
(Tranylcypromine), and its nonamine analog,
cyclopropylbenzene. Drug Metab. Dispos. 29,
217-222.
48.
Draper, A.J., A. Madan, and A. Parkinson (1997).
Inhibition of coumarin 7-hydroxylase activity in
human liver microsomes. Arch. Biochem. Biophys.
341,47-61.
49.
Khojasteh-Bakht, S.C, L.L. Koenigs, R.M. Peter,
W.F.
Trager, and S.D. Nelson (1998). (R)-(+)-
Menthofuran is a potent, mechanism-based inacti-
vator of human liver cytochrome P450 2A6. Drug
Metab. Dispos. 26, 701-704.
50.
Koenigs, L.L. and
W.F.
Trager (1998). Mechanism-
based inactivation of P450 2A6 by furano-
coumarins. Biochemistry 37, 10047-10061.
51.
Heyn, H., R.B. White, and J.C. Stevens (1996).
Catalytic role of cytochrome P450 2B6 in
N-demethylation of ^'-mephenytion. Drug Metab.
Dispos. 24, 948-954.
52.
Stiborova, M., L. Borek-Dohalska, P. Hodek,
J. Mraz, and
E.
Frei (2002). New selective inhibitors
of cytochromes P450 2B and their application to
antimutagenesis of tamoxifen. Arch. Biochem.
Biophys. 403, 41^9.
53.
Ekins, S., M. VandenBranden, B.J. Ring, and
S.A. Wrighton (1997). Examination of purported
probes of human CYP2B6. Pharmacogenetics 7,
165-179.
54.
Ekins, S. and S.A. Wrighton (1999). The role of
CYP2B6 in human xenobiotic metabolism. Drug
Metab. Rev. 31, 719-754.
55.
Rae, J.M., N.V Soukhova, D.A. Flockhart, and
Z.
Desta (2002). Triethylenethiophosphoramide is a
specific inhibitor of cytochrome P450 2B6:
Implications for cyclophosphamide metabolism.
Drug
Metab.
Dispos. 30, 525-530.
56.
Faucette, S.R., R.L. Hawke, E.L. Lecluyse,
S.S. Shord, B. Yan, R.M. Laethem et al. (2000).
Validation of bupropion hydroxylation as a selective
marker of human cytochrome P450 2B6 catalytic
activity. Drug
Metab.
Dispos. 28, 1222-1230.
57.
Richter, T, K. Klein, T.E. Murdter, M. Eichelbaum,
M. Schwab, and U.M. Zanger (2003). Clopidogrel
and ticlopidine are specific mechanism-based
inhibitors of human cytochrome P450 2B6. In
Proceedings of the 13th International Conference
on Cytochromes P450. Prague, Czech Republic,
p.
S119.
58.
Dai, D., D.C. Zeldin, J.A. Blaisdell, B. Chanas,
S.J. Coulter, B.I. Ghanayem et al. (2001). Poly-
morphisms in human CYP2C8 decrease metabo-
lism of the anticancer drug paclitaxel and arachidonic
acid, Pharmacogenetics 11, 597-607.
59.
Harris, J.W, A. Rahman, B.R. Kim, F.P
Guengerich, and J. Collins (1994). Metabolism of
taxol by human hepatic microsomes and human
liver slices: Participation of cytochrome P450 3A4
and an unknown P450 enzyme. Cancer Res. 54,
4026-4035.
60.
Rahman, A., K.R. Korzekwa, J. Grogan, F.J.
Gonzalez, and J.W. Harris (1994). Selective bio-
transformation of taxol to 6 alpha-hydroxytaxol by
human cytochrome P450 2C8. Cancer Res. 54,
5543-5546.
61.
Wen, X., J.S. Wang, J.T. Backman, J. Laitila, and
P.J. Neuvonen (2002). Trimethoprim and sul-
famethoxazole are selective inhibitors of CYP2C8
and CYP2C9, respectively. Drug Metab. Dispos.
30,631-635.
62.
Wang, J.S. and C.L. DeVane (2003). Involvement of
CYP3A4, CYP2C8, and CYP2D6 in the metabolism
of (R)- and (S)-methadone in vitro. Drug Metab.
Dispos. 31, 742-747.
63.
Tang, W, R.A. Stearns, R.W Wang, S.H. Chiu, and
T.A. Baillie (1999). Roles of human cytochrome
P450s 2C9 and 3A4 in the metabolic activation of
diclofenac. Chem. Res. Toxicol. 12, 192-199.
64.
Leemann, T., C. Transon, and P. Dayer (1993).
Cytochrome P450TB (CYP2C): A major monooxy-
genase catalyzing diclofenac 4'-hydroxylation in
human liver. Life Sci. 52, 29-34.
65.
Rettie, A.E., K.R. Korzekwa, K.L. Kunze,
R.F.
Lawrence, A.C. Eddy,
T.
Aoyama et al. (1992).
Hydroxylation of warfarin by human cDNA-
expressed cytochrome P-450: A role for P-4502C9
in the etiology of (S)-warfarin-drug interactions.
Chem.
Res. Toxicol. 5, 54-59.
66.
Giancarlo, G.M., K. Venkatakrishnan, B.W
Granda, L.L. von Moltke, and D.J. Greenblatt
(2001).
Relative contributions of CYP2C9 and
2C19 to phenytoin 4-hydroxylation in vitro:
Inhibition by sulfaphenazole, omeprazole, and
ticlopidine. Eur J. Clin. Pharmacol. 57, 31-36.
67.
Relling, M.V, T. Aoyama, F.J. Gonzalez, and
U.A. Meyer (1989). Tolbutamide and mephenytoin
650
M.A. Correia
hydroxylation by human cytochrome P450s in the
CYP2C subfamily. J. Pharmacol. Exp. Then 252,
442^47.
68.
Brian, W.R., P.K. Srivastava, D.R. Umbenhauer,
R.S.
Lloyd, and
F.P.
Guengerich (1989). Expression
of a human liver cytochrome P-450 protein with
tolbutamide hydroxylase activity in Saccharomyces
cerevisiae. Biochemistry 28, 4993-4999.
69.
Srivastava, PK., C.H. Yun, PH. Beaune, C. Ged,
and F.P. Guengerich (1991). Separation of human
liver tolbutamine hydroxylase and f5)-mephenytoin
4'-hydroxylase cytochrome P-450 enzymes. Mol.
Pharmacol. 40, 69-79.
70.
Miners, J.O. and D.J. Birkett (1996). Use of tolbu-
tamide as a substrate probe for human hepatic cyto-
chrome P450 2C9. Meth. Enzymol. 212, 139-145.
71.
Lasker, J.M., M.R. Wester, E. Aramsombatdee, and
J.L. Raucy (1998). Characterization of CYP2C19
and CYP2C9 from human liver: Respective roles
in microsomal tolbutamide, S-mephenytoin, and
omeprazole hydroxylation.
Arch.
Biochem. Biophys.
353,
16-24.
72.
Lopez-Garcia, M.P., P.M. Dansette, and D. Mansuy
(1993).
Thiophene derivatives as new mechanism-
based inhibitors of cytochromes P450: Inactivation
of yeast-expressed human liver P450 2C9 by tie-
nilic acid. Biochemistry 33, 166-175.
73.
Lopez-Garcia, M.P., P.M. Dansette, P. Valadon,
C. Amar, PH. Beaune, F.P Guengerich et
al.
(1993).
Human liver P450s expressed in yeast as tools for
reactive metabolite formation studies: Oxidative
activation of tienilic acid by P450 2C9 and P450
2C10.
Eur J. Biochem. 213, 223-232.
74.
Shimada, T., K.S. Misono, and F.P. Guengerich
(1986).
Human liver microsomal cytochrome
P-450 mephenytoin 4-hydroxylase, a prototype of
genetic polymorphism in oxidative drug metabo-
lism. Purification and characterization of two
similar forms involved in the reaction. J. Biol.
Chem.
261,909-921.
75.
Kaminsky, L.S. (1989). Warfarin as a probe of
cytochromes P450 function. Drug Metab. Rev. 20,
479-487.
76.
Kaminsky, L.S., M.J. Fasco, and F.P. Guengerich
(1981).
Production and apphcation of antibodies to
rat liver cytochrome P-450. Meth. Enzymol. 74,
262-272.
77.
Lang, D. and R. Bocker (1995). Highly sensitive
and specific high-performance liquid chromato-
graphic analysis of 7-hydroxywarfarin, a marker
for human cytochrome P-4502C9 activity. J.
Chromatogr
Biomed.
Appl. 672, 305-309.
78.
Minoletti, C., S. Dijols, RM. Dansette, and
D.
Mansuy (1999). Comparison of the substrate
specificities of human liver cytochrome P450s 2C9
and 2C18: Application to the design of a spec-
ific substrate of CYP 2C18. Biochemistry 38,
7828-7836.
79.
Ha-Duong, N.T., C. Marques-Soares, S. Dijols,
M.A. Sari, P.M. Dansette, and D. Mansuy
Interaction of new sulfaphenazole derivatives with
human liver cytochrome P450 2Cs: Structural
determinants required for selective recognition by
CYP 2C9 and for inhibition of human CYP 2Cs.
Arch.
Biochem. Biophys. 394, 189-200.
80.
Wrighton, S.A., J.C. Stevens, G.W. Becker, and
M. VandenBranden (1993). Isolation and character-
ization of human liver cytochrome P450 2C19:
Correlation between 2C19 and S-mephenytoin 4'-
hydroxylation. Arch. Biochem. Biophys. 306,
240-245.
81.
Goldstein, J.A., M.B. Faletto, M. Romkes-Sparks,
T. Sullivan, S. Kitareewan, J.L. Raucy
etal.
(1994).
Evidence that CYP2C19 is the major (S)-mepheny-
toin 4'-hydroxylase in humans. Biochemistry 33,
1743-1752.
82.
Suzuki, H., M.B. Kneller, R.L. Haining, and
WF Trager, A.E. Rettie (2002). (+)-N-3-Benzyl-
nirvanol and (-)-N-3-benzyl-phenobarbital: New
potent and selective in vitro inhibitors of
CYP2C19. Drug
Metab.
Dispos. 30, 235-239.
83.
Walsky, R.L. and R.S. Obach (2003). Verification
of the selectivity of (+)N-3-benzylnirvanol as a
CYP2C19 inhibitor. Drug
Metab.
Dispos. 31, 343.
84.
Ha-Duong, N.T., S. Dijols, A.C. Macherey, J.A.
Goldstein, PM. Dansette, and D. Mansuy (2001).
Ticlopidine as a selective mechanism-based
inhibitor of human cytochrome P450 2C19.
Biochemistry
4(i,
12112-12122.
85.
Ha-Duong, N.T., S. Dijols, A.C. Macherey,
PM. Dansette, and
D.
Mansuy (2001). Inhibition by
ticlopidine and its derivatives of human liver
cytochrome P450. Mechanism-based inactivation
of CYP 2C19 by ticlopidine. Adv. Exp. Med. Biol.
500,
145-148.
86.
Gonzalez, F.J., T. Matsunaga, K. Nagata, U.A.
Meyer, D.W Nebert, J. Pastewka et al. (1987).
Debrisoquine 4-hydroxylase: Characterization of a
new P450 gene subfamily, regulation, chromoso-
mal mapping, and molecular analysis of
the
DA rat
polymorphism. DNA 6,
149-161.
87.
Gut, J., T. Catin, P Dayer, T. Kronbach, U. Zanger,
and U.A. Meyer (1986). Debrisoquine/sparteine-
type polymorphism of drug oxidation. Purification
and characterization of two functionally different
human liver cytochrome P-450 isozymes involved
in impaired hydroxylation of the prototype
substrate bufuralol. J. Biol. Chem. 261,
11734-11743.
88.
Kronbach,
T.
(1991). Bufuralol, dextromethorphan,
and debrisoquine as prototype substrates for human
P450IID6. Meth. Enzymol. 206, 509-517.
Human and Rat Liver Cytochromes P450
651
89.
Otton, S.V, T. Inaba, and W. Kalow (1984).
Competitive inhibition of sparteine oxidation in
human Hver by beta-adrenoceptor antagonists and
other cardiovascular drugs. Life Sci. 34, 73-80.
90.
Bertelsen, K.M., K. Venkatakrishnan, L.L. Von
Moltke, R.S. Obach, and D.J. Greenblatt (2003).
Apparent mechanism-based inhibition of human
CYP2D6 in vitro by paroxetine: Comparison with
fluoxetine and quinidine. Drug
Metab.
Dispos. 31,
289-293.
91.
Bloomer, J.C, F.R. Woods, R.E. Haddock,
M.S.
Lennard, and G.T. Tucker (1992). The role of
cytochrome P4502D6 in the metabolism of parox-
etine by human liver microsomes. Br. J. Clin.
Pharmacol. 33, 521-523.
92.
Sindrup, S.H., K. Brosen, and L.F. Gram (1992).
Pharmacokinetics of the selective serotonin reup-
take inhibitor paroxetine: Nonlinearity and relation
to the sparteine oxidation polymorphism. Clin.
Pharmacol. Ther 51, 288-295.
93.
Sindrup, S.H., K. Brosen, L.F. Gram, J. Hallas,
E. Skjelbo, A. Allen et ai (1992). The relationship
between paroxetine and the sparteine oxidation
polymorphism. Clin. Pharmacol. Ther 51,
278-287.
94.
Dayer, P, T Leemann, and R. Striberni (1989).
Dextromethorphan O-demethylation in liver
microsomes as a prototype reaction to monitor
cytochrome P-450 dbl activity. Clin. Pharmacol.
Ther.
45, 34^0.
95.
Rodrigues, A.D. (1996). Measurement of human
liver microsomal cytochrome P450 2D6 activity
using [O-methyl-^'^Cldextromethorphan as sub-
strate. Meth. Enzymol 111, 186-195.
96.
Palamanda, J.R., C.N. Casciano, L.A. Norton,
R.P Clement, L.V Favreau, C. Lin et ai (2001).
Mechanism-based inactivation of CYP2D6 by
5-fluoro-2-[4-[(2-phenyl-1 H-imidazol-5-yl) methyl]-
l-piperazinyl]pyrimidine. Drug
Metab.
Dispos. 29,
863-867.
97.
Yamazaki, H., Z. Guo, and EP Guengerich (1995).
Selectivity of cytochrome P4502E1 in chlorzoxa-
zone 6-hydroxylation. Drug Metab. Dispos. 23,
438^40.
98.
Peter, R., R. Bocker, PH. Beaune, M. Iwasaki, EP
Guengerich, and C.S. Yang (1990). Hydroxylation
of chlorzoxazone as a specific probe for human liver
cytochrome
P-450IIE1.
Chem.
Res.
Toxicol.
3, 566-
573.
Erratum in: Chem. Res.
Toxicol.
4, 389, 1991.
99.
Feierman, D.E. and A.L Cederbaum (1986).
Inhibition of microsomal oxidation of ethanol by
pyrazole and 4-methylpyrazole in vitro. Increased
effectiveness after induction by pyrazole and
4-methylpyrazole. Biochem. J. 239, 671-677.
100.
Yang, C.S., C.J. Patten, H. Ishizaki, and J.S.H. Yoo
(1992).
Induction, purification, and characterization
of cytochrome P450IIE1. Meth. Enzymol. 206,
595-603.
101.
Tassaneeyakul, W., M.E. Veronese, D.J. Birkett,
EJ. Gonzalez, and J.O. Miners (1993). Validation
of 4-nitrophenol as an in vitro substrate probe
for human liver CYP2E1 using cDNA expression
and microsomal kinetic techniques. Biochem.
Pharmacol. 46, 1975-1981.
102.
Guengerich, EP, D.H. Kim, and M. Iwasaki
(1991).
Role of human cytochrome P-450 IIEl in
the oxidation of many low molecular weight cancer
suspects. Chem. Res.
Toxicol.
4, 168-179.
103.
Kharasch, E.D., D.C. Hankins, C. Jubert, K.E.
Thummel, and J.K. Taraday (1999). Lack of single-
dose disulfiram effects on cytochrome P-450 2C9,
2C19,
2D6, and 3A4 activities: Evidence for speci-
ficity toward P-450 2E1. Drug
Metab.
Dispos. 11,
717-723.
104.
Chang, TK.H., EJ. Gonzalez, and D.J. Waxman
(1994).
Evaluation of triacetyloleandomycin, a-
naphthoflavone and diethyldithiocarbamate as
selective chemical probes for inhibition of human
cytochromes P450. Arch. Biochem. Biophys. 311,
437^42.
105.
Wrighton, S.A., PE. Thomas, D.T. Molowa,
M. Haniu, J.E. Shively, S.L. Maines et al. (1986).
Characterization of ethanol-inducible human liver
N-nitrosodimethylamine demethylase. Biochemistry
25,6731-6735.
106.
Yoo, J.S., EP Guengerich, and C.S. Yang (1988).
Metabolism of N-nitrosodialkylamines by human
liver microsomes. Cancer Res. 48, 1499-1504.
107.
Yamazaki, H., Y Inui, C.H. Yun, M. Mimura,
EP.
Guengerich, andT. Shimada
(1992).
Cytochrome
P450 2E1 and 2A6 enzymes as major catalysts for
metabolic activation of A^-nitrosodialkylamines and
tobacco-related nitrosamines in human liver micro-
somes.
Carcinogenesis
13, 1789-1794.
108.
Yamazaki,
H.,
Y.
Oda,
Y.
Funae, S. Imaoka, Y Inui,
EP Guengerich et al. (1992). Participation of rat
liver cytochrome P450 2E1 in the activation of
N-nitrosodimethylamine and N-nitrosodiethyl-
amine to products genotoxic in an acetyltrans-
ferase-overexpressing Salmonella typhimurium
strain (NM2009). Carcinogenesis 13, 979-985.
109.
Waxman, D.J., C. Attisano, EP Guengerich, and
D.P. Lapenson (1988). Human liver microsomal
steroid metabolism: Identification of the major
microsomal steroid hormone 6 beta-hydroxylase
cytochrome P-450 enzyme. Arch. Biochem.
Biophys. 263, 424^36.
110.
Gillam, E.M., T Baba, B.R. Kim, S. Ohmori, and
EP Guengerich (1993). Expression of modified
human cytochrome P450 3A4 in Escherichia coli
and purification and reconstitution of the enzyme.
Arch.
Biochem. Biophys. 305,
123-131.
652
M.A. Correia
111.
Guengerich, F.R (1990). Mechanism-based inacti-
vation of human liver cytochrome P-450 IIIA4 by
gestodene. Chem. Res.
Toxicol.
3,
363-371.
112.
Guengerich, F.R, M.V Martin, RH. Beaune,
R Kremers, T.
Wolff,
and D.J. Waxman (1986).
Characterization of rat and human liver microso-
mal cytochrome P-450 forms involved in
nifedipine oxidation, a prototype for genetic poly-
morphism in oxidative drug metabolism. J. Biol.
C/zem. 261, 5051-5060.
113.
Gonzalez, F.J., B.J. Schmid, M. Umeno, O.W.
Mcbride, J.R Hardwick, U.A. Meyer et al. (1988).
Human
P450RCN1:
Sequence, chromosome local-
ization, and direct evidence through cDNA expres-
sion that P450PCN1 is nifedipine oxidase.
DMA
7,
79-86.
114.
Guengerich, F.R, W.R. Brian, M. Iwasaki,
M.A. Sari, C. Baarnhielm, and P. Bemtsson
(1991).
Oxidation of dihydropyridine calcium
channel blockers and analogues by human liver
cytochrome P-450 IIIA4. J. Med. Chem. 34,
1838-1844.
115.
Varhe, A., M.B. Klaus, T. Olkkola, and
P.J. Neuvonen (1994). Oral triazolam is potentially
hazardous to patients receiving systemic antimy-
cotics.
Clin. Pharmacol.
Ther.
56, 601-607.
116.
Watkins, RB., S.A. Wrighton, R Maurel,
E.G. Schuetz, G. Mendez-Picon, G.A. Parker et al.
(1985).
Identification of an inducible form of
cytochrome P-450 in human liver. Proc. Natl.
Acad.
Sci. USA 82, 6310-6314.
117.
Watkins, RB., S.A. Murray, L.G. Winkelman,
D.M. Heuman, S.A. Wrighton, and PS. Guzelian
(1989).
Erythromycin breath test as an assay of
glucocorticoid-inducible liver cytochromes P-450.
J. Clin. Invest. 83, 688-697.
118.
Thummel, K.E., C.A. Lee, K.L. Kunze,
S.D. Nelson, and J.T. Slattery (1993). Oxidation of
acetaminophen to N-acetyl-p-aminobenzoquinone
imine by human CYP3A4. Biochem. Pharmacol.
45,
1563-1569.
119.
Renaud, J.R, C. Cullin, D. Pompon, R Beaune, and
D.
Mansuy (1990). Expression of human liver
cytochrome P450 IIIA4 in yeast. A functional
model for the hepatic enzyme. Eur J. Biochem.
194:889-896.
120.
Kronbach, T., D. Mathys, M. Umeno,
F.J. Gonzalez, and U.A. Meyer (1989). Oxidation
of midazolam and triazolam by human liver cyto-
chrome P450IIIA4. Mol. Pharmacol. 36, 89-96.
121.
Thummel, K.E., D.D. Shen, T.D. PodoU,
K.L. Kunze, WE Trager, PS. Hartwell et al.
(1994).
Use of midazolam as a human cytochrome
P450 3A probe: I. In vitro-in vivo correlations in
liver transplant patients. J. Pharmacol. Exp. Ther
111,
549-556.
122.
Stresser, M.D., M.I. Broudy, S.S. Dehal,
C.J. Patten, and C.L. Crespi (2002). Azamulin is
superior to ketoconazole as a selective CYP3A
inhibitor probe. Drug Metab. Rev. Abstracts from
the 11th North American ISSX Meeting, Orlando,
FL,
USA, Oct. 27-Oct. 31, Vol. 34, Abs. 355,
p.
178.
123.
Jang, G.R., S.A. Wrighton, and L.Z. Benet (1996).
Identification of CYP3A4 as the principal enzyme
catalyzing mifepristone (RU 486) oxidation in
human liver microsomes. Biochem. Pharmacol.
52,753-761.
124.
He, K., T.F
Woolf,
and RE Hollenberg (1999).
Mechanism-based inactivation of cytochrome
P-450-3A4 by mifepristone (RU486).
J.
Pharmacol.
Exp.
Ther 288, 791-797.
125.
Khan, K.K., Y.Q. He, M.A. Correia, and
J.R. Halpert (2002). Differential oxidation of
mifepristone by cytochromes P450 3A4 and 3A5:
Selective inactivation of P450 3A4. Drug Metab.
Dispos. 30, 985-990.
126.
Jones, D.R., J.C. Gorski, M.A. Hamman, B.S.
Mayhew, S. Rider, and S.D. Hall (1999). Diltiazem
inhibition of cytochrome P-450 3A activity is due
to metabolite intermediate complex formation. J.
Pharmacol. Exp. Ther 290, 1116-1125.
127.
Wrighton, S.A., W.R. Brian, M.A. Sari,
M. Iwasaki, F.R Guengerich, J.L. Raucy et al.
(1990).
Studies on the expression and metaboHc
capabilities of human Hver cytochrome P450IIIA5
(HLp3). Mol. Pharmacol. 38, 207-213.
128.
Gillam, E.M., Z. Guo, YE Ueng, H. Yamazaki,
1.
Cock, RE. Reilly et al. (1995). Expression of
cytochrome P450 3A5 in Escherichia coli: Effects
of
5'
modification, purification, spectral character-
ization, reconstitution conditions, and catalytic
activities. Arch. Biochem. Biophys. 317, 374-384.
Erratum
in:
Arch.
Biochem.
Biophys.
318,498,1995.
129.
Gorski, J.C, S.D. Hall, D.R. Jones,
M. VandenBranden, and S.A. Wrighton (1994).
Regioselective biotransformation of midazolam by
members of the human cytochrome P450 3A
(CYP3A) subfamily. Biochem. Pharmacol. 47,
1643-1653.
130.
Gorski, J.C, D.R. Jones, M.A. Hamman, S.A.
Wrighton, and S.D. Hall (1999). Biotrans-
formation of alprazolam by members of the human
cytochrome P4503A subfamily. Xenobiotica 29,
931-944.
131.
Williams, J.A., B.J. Ring, VE. Cantrell, D.R. Jones,
J. Eckstein, K. Ruterbories et al. (2002). Com-
parative metabolic capabilities of CYP3A4,
CYP3A5,
and CYP3A7. Drug Metab. Dispos. 30,
883-891.
132.
Parimoo, B., VM. Mishin, CM. Busch, and
RE.
Thomas (2003). Identification of epitopes on
Human and Rat Liver Cytochromes P450
653
cytochrome P450 3A4/5 recognized by mono-
clonal antibodies. Arch. Biochem. Biophys. 414,
244-254.
133.
Kitada, M., T. Kamataki, K. Itahashi, T. Rikihisa,
and
Y.
Kanakubo (1987). P-450 HFLa, a form of
cytochrome P-450 purified from human fetal
livers,
is the 16 alpha-hydroxylase of dehydro-
epiandrosterone 3-sulfate. J. Biol. Chem. 161,
13534-13537.
134.
Nakamura, H., N. Torimoto, I. Ishii, N. Ariyoshi,
H. Nakasa, S. Ohmori et al (2003). CYP3A4 and
CYP3A7-mediated carbamazepine 10,11 -epoxida-
tion are activated by differential endogenous
steroids. Drug
Metab.
Dispos. 31, 432-^38.
135.
Gillam, E.M., R.M. Wunsch, YE Ueng, T.
Shimada, RE. Reilly, T. Kamataki et al. (1997).
Expression of cytochrome P450 3A7 in
Escherichia coli: Effects of 5' modification and
catalytic characterization of recombinant enzyme
expressed in bicistronic format with NADPH-
cytochrome P450 reductase. Arch. Biochem.
Biophys. 346, 81-90.
136.
Kawashima, H., E. Kusunose, Y Kikuta,
H. Kinoshita, S. Tanaka, S. Yamamoto et al.
(1994).
Purification and cDNA cloning of human
liver CYP4A fatty acid co-hydroxylase.
J.
Biochem.
116,74-80.
137.
Powell, PK., I.
Wolf,
and J.M. Lasker (1996).
Identification of CYP4A11 as the major lauric
acid omega-hydroxylase in human liver micro-
somes. Arch. Biochem. Biophys. 335, 219-226.
138.
Clarke, S.E., S.J. Baldwin, J.C. Bloomer,
A.D.
Ayrton, R.S. Sozio, and R.J. Chenery (1994).
Lauric acid as a model substrate for the simultaneous
determination of cytochrome P450 2E1 and 4A
in hepatic microsomes. Chem. Res. Toxicol. 7,
836-842.
139.
Amet, Y, E Berthou, S. Baird, Y Dreano, J.P Bail,
and J.E Menez (1995). Validation of the (omega-1)-
hydroxylation of lauric acid as an in vitro sub-
strate probe for human liver CYP2E1. Biochem.
Pharmacol. 50, 1775-1782.
140.
Savas, U, M.H. Hsu, and E.E Johnson (2003).
Differential regulation of human CYP4A genes by
peroxisome proliferators and dexamethasone.
Arch.
Biochem. Biophys. 409, 212-220.
141.
Oglivie, B.W., S.M. Otradovec, B.L. Paris,
J.A. Scheinkoenig, P.W. Carrott, S.P. Loecker et al.
(2000).
10-(imidazolyl)-decanoic acid (10-IDA) is
a selective and potent inhibitor of CYP4A9/11.
Drug. Metab. Rev. Abstracts from the 10th North
American ISSX Meeting, Indianapolis, IN, USA,
Vol. 32 (Suppl. 2), Abs. 188, p. 230.
142.
Miyata, N., K. Taniguchi, T. Seki, T. Ishimoto,
M. Sato-Watanabe, Y Yasuda et al. (2001).
HET0016, a potent and selective inhibitor of 20-
HETE synthesizing enzyme. Br J. Pharmacol.
133,
325-329.
143.
Powell, PK., I.
Wolf,
R. Jin, and J.M. Lasker
(1998).
Metabolism of arachidonic acid to 20-
hydroxy-5,8,ll,14-eicosatetraenoic acid by P450
enzymes in human liver: Involvement of CYP4F2
and CYP4A11. J. Pharmacol. Exp. Ther 285,
1327-1336.
144.
Jin, R., D.R. Koop, J.L. Raucy, and J.M. Asker
(1998).
Role of human CYP4F2 in hepatic catabo-
lism of the proinflammatory agent leukotriene B4.
Arch.
Biochem. Biophys. 359, 89-98.
145.
Zhang, X., L. Chen, and J.P Hardwick (2000). Pro-
moter activity and regulation of the CYP4F2
leukotrieneB(4) omega-hydroxylase gene by per-
oxisomal proliferators and retinoic acid in HepG2
cells.
Arch. Biochem. Biophys. 378, 364-376.
146.
Shak, S. and I. Goldstein (1984). Omega-oxidation
is the major pathway for the catabolism of
leukotriene B4 in human polymorphonuclear
iQukocytQS.
J. Biol. Chem. 259, 10181-10187.
147.
Bylund, I, M. Bylund, and E.H. Oliw (2001).
cDNA cloning and expression of CYP4F12, a
novel human cytochrome P450. Biochem. Biophys.
Res.
Commun. 280, 892-897.
148.
Maeda, Y.R., G. Eggertsen, B. Nyberg,
T. Setoguchi, K.I. Okuda, K. Einarsson et al.
(1995).
Immunochemical determination of human
cholesterol 7 alpha-hydroxylase. Eur. J. Biochem.
IIH, 144-148.
149.
Gafvels, M., M. Olin, B.P Chowdhary,
T. Raudsepp, U. Andersson, B. Persson et al.
(1999).
Structure and chromosomal assignment
of the sterol 12alpha-hydroxylase gene (CYP8B1)
in human and mouse: Eukaryotic cytochrome
P-450 gene devoid of introns. Genomics 56,
184-196.
150.
Chun, Y.J., S.Y Ryu, T.C. Jeong, and M.Y Kim
(2001).
Mechanism-based inhibition of human
cytochrome P450 lAl by rhapontigenin. Drug.
Metab. Dispos. 29, 389-393.
151.
Guengerich, RP, G.A. Dannan, S.T. Wright, M.V
Martin, and L.S. Kaminsky (1982). Purification
and characterization of liver microsomal cyto-
chromes P-450: Electrophoretic, spectral, catalytic,
and immunochemical properties and inducibility
of eight isozymes isolated from rats treated with
phenobarbital or beta-naphthoflavone. Biochemistry
21,
6019-6030.
152.
Sesardic, D., R.J. Edwards, D.S. Davies, PE.
Thomas, W Levin, and A.R. Boobis (1990). High
affinity phenacetin O-deethylase is catalysed
specifically by cytochrome P450d (P450IA2) in the
liver of the rat. Biochem. Pharmacol. 39, 489^98.
153.
Sarkar, M.A. and B.J. Jackson (1994).
Theophylline N-demethylations as probes for
654 M.A. Correia
P4501A1 and P4501A2. Drug Metab. Dispos. 22,
827-834.
154.
Chun, Y.J., S. Kim, D. Kim, S.K. Lee, and
F.P.
Guengerich (2001). A new selective and potent
inhibitor of human c3^ochrome P450 IBl and its
application to antimutagenesis. Cancer Res. 61,
8164-8170. Erratum in: Cancer Res. 62, 1232,
2002.
155.
Shimada, T, H. Yamazaki, M. Foroozesh,
N.E.
Hopkins, W.L. Alworth, F.P. Guengerich
(1998).
Selectivity of polycyclic inhibitors for
human cytochrome P450s lAl, 1A2, and IBl.
Chem.
Res.
Toxicol.
11, 1048-1056.
156.
Shimada, T., F. Tsumura, E.M. Gillam,
FP Guengerich, and K. Inoue (2000). Roles of
NADPH-P450 reductase in the 0-deethylation of
7-ethoxycoumarin by recombinant human cyto-
chrome P4501B1 variants in Escherichia coli.
Protein Expr
Purif.
20, 73-80.
157.
Badawi, A.F, E.L. Cavalieri, and E.G. Rogan
(2000).
Effect of chlorinated hydrocarbons on
expression of cytochrome P450 lAl, 1A2 and IBl
and 2- and 4-hydroxylation of 17beta-estradiol in
female Sprague-Dawley rats. Carcinogenesis 21,
1593-1599.
158.
Hayes, C.L., D.C. Spink, B.C. Spink, J.Q. Cao, N.J.
Walker, and T.R. Sutter (1996). 17 beta-estradiol
hydroxylation catalyzed by human cytochrome
P450 IBl. Proc. Natl.
Acad.
Sci. USA 93,
9776-9781.
159.
Levin, W, RE. Thomas, D.E. Ryan, and A.W.
Wood (1987). Isozyme specificity of testosterone
7a-hydroxylation in rat hepatic microsomes: Is
cytochrome P-450a the sole catalyst?
Arch.
Biochem.
Biophys. 258, 630-635.
160.
Waxman, D.J., A. Ko, and C. Walsh (1983).
Regioselectivity and stereoselectivity of androgen
hydroxylations catalyzed by cytochrome P-450
isozymes purified from phenobarbital-induced rat
liver. J. Biol. Chem. 258, 11937-11947.
161.
Waxman, D.J. (1988). Interactions of hepatic
cytochromes P-450 with steroid hormones.
Regioselectivity and stereoselectivity of steroid
metabolism and hormonal regulation of rat P-450
enzyme expression. Biochem. Pharmacol. 37,
71-84.
162.
Wood, A.W, D.R. Ryan, RE. Thomas, and
W Levin (1983). Regio- and stereoselective
metabolism of two Cjp steroids by five highly puri-
fied and reconstituted rat hepatic cytochrome
P450 isozymes. J. Biol. Chem. 258, 8839-8847.
163.
Arlotto, M.P, J.M. Trant, and R.W Estabrook
(1992).
Measurement of steroid hydroxylation
reactions by high-performance liquid chromatog-
raphy as indicator of P450 identity and function.
Meth.
Enzymol 206, 454-462.
164.
Smith, S.J., K.R. Korzekwa, T. Aoyama,
F.J. Gonzalez, J.F. Darbyshire, K. Sugiyama et al.
(1992).
12 alpha-hydroxytestosterone. A hitherto
unidentified testosterone metabolite produced by
cytochrome P-450 2A2. Drug Metab. Dispos. 20,
566-571.
165.
Lunetta, J.M., K. Sugiyama, and M.A. Correia
(1989).
Secobarbital-mediated inactivation of rat
liver cytochrome P-450b: A mechanistic reap-
praisal. Mol. Pharmacol. 35, 10-17.
166.
He, K., A.M. Falick, B. Chen, F Nilsson, and M.A.
Correia (1996). Identification of the heme adduct
and an active site peptide modified during mecha-
nism-based inactivation of rat liver cytochrome
P450 2B1 by secobarbital. Chem. Res.
Toxicol.
9,
614-622.
167.
Lubet, R.A., R.T. Mayer, J.W Cameron, R.W. Nims,
M.D. Burke, T Wolff e/ al (1985). Dealkylation of
pentoxyresorufin: A rapid and sensitive assay for
measuring induction of cytochrome(s) P-450 by
phenobarbital and other xenobiotics in the rat. Arch.
Biochem. Biophys. 238, 43^8.
168.
Halpert, J., J.Y. Jaw, C. Balfour, and
L.S.
Kaminsky (1990). Selective inactivation by
chlorofluoroacetamides of the major phenobarbi-
tal-inducible form(s) of rat liver cytochrome
P-450. Drug Metab Dispos. 18, 168-174.
169.
Hopkins, N.E., M.K. Foroozesh, and W.L. Alworth
(1992).
Suicide inhibitors of cytochrome P450
lAl and P450 2B1. Biochem. Pharmacol. 44,
787-796.
170.
Roberts, E.S., N.E. Hopkins, M. Foroozesh,
W.L. Alworth, J.R. Halpert, and PF Hollenberg
et al. (1997). Inactivation of cytochrome P450s
2B1,
2B4, 2B6, and 2B11 by arylalkynes. Drug
Metab Dispos. 25, 1242-1248.
171.
Swinney, D.C, D.E. Ryan, RE. Thomas, and
W Levin (1987). Regioselective progesterone
hydroxylation catalyzed by eleven rat hepatic
cytochrome P-450 isozymes. Biochemistry 26,
7073-7083.
172.
Halpert, J., J.Y. Jaw, and C. Balfour (1989).
Specific inactivation by 17p-substituted steroids
of rabbit and rat liver cytochromes P-450 res-
ponsible for progesterone 21-hydroxylation. Mol.
Pharmacol. 34, 148-156.
173.
Kobayashi, K., K. Urashima, N. Shimada, and
K. Chiba (2003). Selectivities of human cyto-
chrome P450 inhibitors toward rat P450 isoforms:
Study with cDNA-expressed systems of the rat.
Drug
Metab.
Dispos. 31, 833-836.
174.
Masubuchi, Y, A. Ose, and T. Horie (2001).
Mechanism-based inactivation of CYP2C11 by
diclofenac. Drug
Metab.
Dispos. 29, 1190-1195.
175.
Shen, S., S.J. Hargus, B.M. Martin, and L.R. Pohl
(1997).
Cytochrome P4502C11 is a target of
Human and Rat Liver Cytochromes P450
655
diclofenac covalent binding in rats. Chem. Res.
Toxicol. 10, 420-423.
176.
MacGeoch, C, E.T. Morgan, J. Halpert, and
J.A. Gustafsson (1984). Purification, characteriza-
tion, and pituitary regulation of the sex-specific
cytochrome P-450 15 beta-hydroxylase from liver
microsomes of untreated female rats. J. Biol.
Chem.
259, 15433-15439.
177.
Wan, J., S. Imaoka, T. Chow,
T.
Hiroi,
Y.
Yabusaki,
and Y. Funae (1997). Expression of four rat
CYP2D isoforms in Saccharomyces cerevisiae and
their catalytic specificity. Arch. Biochem. Biophys.
348,
383-390.
178.
Chow, T., S. Imaoka,
T.
Hiroi, and Y. Funae (1999).
Developmental changes in the catalytic activity
and expression of CYP2D isoforms in the rat liver.
DrugMetab. Dispos. 11, 188-192.
179.
Lin, L.Y., M. Fujimoto, E.W. Distefano,
D.A. Schmitz, A. Jayasinghe, and A.K. Cho
(1996).
Selective mechanism-based inactivation
of rat CYP2D by 4-allyloxymethamphetamine.
J. Pharmacol. Exp. Then 111, 595-603.
180.
Larrey, D., L.M. Distlerath, G.A. Dannan,
G.R. Wilkinson, and F.R Guengerich (1984).
Purification and characterization of the rat liver
microsomal cytochrome P-450 involved in the
4-hydroxylation of debrisoquine, a prototype for
genetic variation in oxidative drug metabolism.
Biochemistry 23, 2787-2795.
181.
Tanaka, E. (2001). Chlorzoxazone: A probe drug the
metabolism of which can be used to monitor
one-point blood sampling in the carbon tetrachloride-
intoxicated rat. Hum. Exp.
Toxicol.
20, 381-385.
182.
Mizuno, D., E. Tanaka, K. Tanno, and S. Misawa
(2000).
Chlorzoxazone: A probe drug whose
metabolism can be used to monitor toluene
exposure in rats. Arch.
Toxicol.
74, 139-144.
183.
Mathews, J.M., A.S. Etheridge, J.H. Raymer, S.R.
Black, D.W Pulliam Jr., and J.R. Bucher (1998).
Selective inhibition of cytochrome P450 2E1 in
vivo and in vitro with trans-1,2-dichloroethylene.
Chem.
Res. Toxicol. 11, 778-785.
184.
Yoo, J.S., T.J. Smith, S.M. King, M.J. Lee,
RE.
Thomas, and C.S. Yang (1992). Modulation of
the levels of cytochromes P450 in rat liver and
lung by dietary lipid. Biochem. Pharmacol. 43,
2535-2542.
185.
Yamazaki, H.,
Y.
Oda, Y Funae, S. Imaoka, Y Inui,
F.P.
Guengerich et al. (1992). Participation of rat
liver cytochrome P450 2E1 in the activation of
N-nitrosodimethylamine and N-nitrosodiethyl-
amine to products genotoxic in an acetyltrans-
ferase-overexpressing Salmonella typhimurium
strain (NM2009). Carcinogenesis 13, 979-985.
186.
Brady, J.F., H. Ishizaki, J.M. Fukuto, M.C. Lin,
A. Fadel, J.M. Gapac et al. (1991). Inhibition of
cytochrome P-450 2E1 by diallyl sulfide and its
metabolites. Chem. Res.
Toxicol.
4, 642-647.
187.
Jin, L. and TA. BaiUie (1997). Metabohsm of the
chemoprotective agent diallyl sulfide to glutathione
conjugates in
rats.
Chem.
Res. Toxicol 10, 318-327.
188.
Premdas, PD., R.J. Bowers, and RG. Forkert
(2000).
Inactivation of hepatic CYP2E1 by an
epoxide of diallyl sulfone. J. Pharmacol. Exp.
Ther 293, 1112-1120.
189.
Ishizaki, H., J.F Brady, S.M. Ning, and C.S. Yang
(1990).
Effect of phenethyl isothiocyanate on micro-
somal N-nitrosodimethylamine metabolism and other
monooxygenase
activities.
Xenobiotica 20, 255-264.
190.
Sonderfan, A.J., M.R Arlotto, D.R. Dutton,
S.K. McMillen, and A. Parkinson (1987).
Regulation of testosterone hydroxylation by rat
liver microsomal cytochrome P-450. Arch.
Biochem. Biophys. 255,
27-41.
191.
Underwood, M.C, J.R. Cashman, and M.A.
Correia (1992). Specifically designed thiosteroids
as active site-directed probes for fiinctional dissec-
tion of cytochrome P-450 3A isozymes. Chem.
Res.
Toxicol. 5,
42-53.
192.
Wrighton, S.A., R Maurel, E.G. Schuetz,
RB.
Watkins, B. Young, and RS. Guzehan (1985).
Identification of the cytochrome P-450 induced by
macrolide antibiotics in rat liver as the glucocorti-
coid responsive cytochrome P-450p. Biochemistry
24,2171-2178.
193.
Watkins, RB., S.A. Wrighton, E.G. Schuetz,
R Maurel, and RS. Guzelian (1986). Macrolide
antibiotics inhibit the degradation of the glucocor-
ticoid-responsive cytochrome P-450p in rat hepa-
tocytes in vivo and in primary monolayer culture.
J. Biol. Chem. 261, 6264-6271.
194.
Wang, H., K.L. NapoH, and H.W. Strobel (2000).
Cytochrome P450 3A9 catalyzes the metabolism
of progesterone and other steroid hormones. Mol
Cell. Biochem. 213, 127-135.
195.
Xue, L., V.G. Zgoda, B. Arison, and M.A. Correia
(2003).
Rat liver
CYP3A9:
Structure-function rela-
tionships to its human liver orthologs: Site-directed
mutagenesis to an efficient progesterone dihydrox-
ylase. Arch. Biochem. Biophys. 409, 113-126.
196.
Gibson, G.G., T.C. Orton, and RR Tamburini
(1982).
Cytochrome P-450 induction by clofibrate:
Purification and properties of a hepatic cyto-
chrome P-450 relatively specific for the 12- and
11-hydroxylation of dodecanoic acid (lauric acid).
Biochem. J. 203, 161-168.
197.
CaJacob, C.A., WK. Chan, E. Shepard, and
RR. Ortiz de Montellano (1988). The catalytic site
of rat hepatic lauric acid omega-hydroxylase.
Protein versus prosthetic heme alkylation in the
omega-hydroxylation of acetylenic fatty acids. J.
Biol. Chem. 263, 18640-18649.
656
M.A. Correia
198.
Ortiz de Montellano, P.R. and N.O. Reich (1984).
Specific inactivation of hepatic fatty acid hydrox-
ylases by acetylenic fatty
acids.
J.
Biol. Chem. 259,
4136-4141.
199.
Chiang, J.Y. (1991). Reversed-phase high-
performance liquid chromatography assay of
cholesterol 7 alpha-hydroxylase. Meth. Enzymol.
206,483-491.
200.
Raucy, J.L., J.M. Lasker, C.S. Lieber, and
M.
Black
(1989).
Acetaminophen activation by human liver
cytochromes P450nEl and P450IA2. Arch.
Biochem. Biophys. Ill, 270-283.
201.
Sinclair, J., E. JefFery, S. Wrighton, V Kostrubsky,
J. Szakacs, S. Wood, and R Sinclair (1998).
Alcohol-mediated increases in acetaminophen
hepatotoxicity: role of CYP2E and CYP3A.
Biochem. Pharmacol. 55, 1557-1565.
202.
Imaoka, S., K. Inoue, and Y. Funae (1988).
Aminopyrine metabolism by multiple forms of
cytochrome P-450 from rat liver microsomes:
Simultaneous quantitation of four aminopyrine
metabolites by high-performance liquid chromatog-
raphy. Arch. Biochem. Biophys. 265, 159-170.
203.
Bornheim, L.M., M.C. Underwood, P. Caldera,
A.E. Rettie, W.E Trager, S.A. Wrighton et al.
(1987).
Inactivation of multiple hepatic cj^o-
chrome P-450 isozymes in rats by allyhsopropy-
lacetamide: Mechanistic implications. Mol.
Pharmacol. 32, 299-308.
204.
Nebert, D.W (1982). Genetic differences in
the induction of monooxygenase activities by
polycyclic aromatic compounds. In J.B.
Schenkman and D. Kupfer (eds). Hepatic
Cytochrome P-450 Monooxygenase System.
Pergamon Press, New York, NY, pp.
269-291.
205.
Prough, R.A., M.D. Burke, and R.T. Mayer (1978).
Direct fluorometric methods for measuring mixed-
fiinction oxidase activity. Meth. Enzymol. 52,
372-377.
206.
Correia, M.A. and G.J. Mannering (1973). Reduced
diphosphopyridine nucleotide synergism of the
reduced triphosphopyridine nucleotide dependent
mixed function oxidase of hepatic microsomes.
Role of
the
Type I drug binding site of cytochrome
P-450. Mol. Pharmacol. 9, 470-485.
207.
Ortiz de Montellano, PR. and A.K. Costa (1986).
Dissociation of cytochrome P-450 inactivation
and induction. Arch. Biochem. Biophys. 251,
514-524.
208.
Mico, B.A., D.A. Federowicz, M.G. Ripple, and
W. Kerns (1988). In vivo inhibition of oxidative
drug metabolism by, and acute toxicity of
1-aminobenzotriazole (ABT).
Biochem.
Pharmacol.
37,2515-2519.
209.
Mugford, C.A., M. Mortillo, B.A. Mico, and J.B.
Tarloff (1992). 1-Aminobenzotriazole-induced
destruction of hepatic and renal cytochromes P450
in male Sprague-Dawley rats. Fundam. Appl.
Toxicol. 19, 43-49.
210.
Levine, M. and G.D. Bellward (1995). Effect of
cimetidine on hepatic cytochrome P450: Evidence
for formation of a metabolite-intermediate com-
plex. DrugMetab. Dispos. 23, 1407-1411.
211.
Levine, M., E.Y. Law, S.M. Bandiera, T.K. Chang,
and G.D. Bellward (1998). In vivo cimetidine
inhibits hepatic CYP2C6 and CYP2C11 but not
CYPlAl in adult male rats. J. Pharmacol. Exp.
Then 284, 493-499.
212.
Gerber, M.C, G.A. Tejwani, N. Gerber, and J.R.
Bianchine (1985). Drug interactions with cimeti-
dine:
An update. Pharmacol. Ther 11, 353-370.
213.
Smith, S.R. and M.J. Kendall (1988). Ranitidine
versus cimetidine. A comparison of their potential
to cause clinically important drug interactions.
Clin.
Pharmacokinet. 15, 44-56.
214.
Correia, M.A., C. Decker, K. Sugiyama, P Caldera,
L. Bornheim, S.A. Wrighton et al. (1987).
Degradation of rat hepatic cj^ochrome P-450
heme by 3,5-dicarbethoxy-2,6-dimethyl-4-
ethyl-l,4-dihydropyridine to irreversibly bound
protein adducts. Arch. Biochem. Biophys. 258,
436-451.
215.
Lesca, P., E. Rafidinarivo, P. LeCointe, and
D.
Mansuy (1979). A class of strong inhibitors of
microsomal monooxygenases: The ellipticines.
Chem.
Biol. Interact. 24, 189-198.
216.
Tassaneeyakul, W, D.J. Birkett, M.E. Veronese,
M.E. McManus, R.H. Tukey, L.C. Quattrochi et al.
(1993).
Specificity of substrate and inhibitor
probes for human cytochromes P450 lAl and
1A2.
J. Pharmacol. Exp. Ther 265, 401^07.
217.
Hemeryck, A. and FM. Belpaire (2002). Selective
serotonin reuptake inhibitors and cytochrome
P-450 mediated drug-drug interactions: An update.
Curr Drug. Metab. 3, 13-37.
218.
Richelson, E. (1997). Pharmacokinetic drug inter-
actions of new antidepressants: A review of the
effects on the metabolism of other drugs. Mayo
Clin.
Proc. 72, 835-847.
219.
Letteron, P., V Descatoire, D. Larrey, M. Tinel,
J. Geneve, and
D.
Pessayre (1986). Inactivation and
induction of cytochrome P-450 by various pso-
ralen derivatives in rats. J. Pharmacol. Exp. Ther
238,
685-692.
220.
Koenigs, L.L. and WF Trager (1998). Mechanism-
based inactivation of cytochrome P450 2B1 by
8-methoxypsoralen and several other furano-
coumarins. Biochemistry 37, 13184-13193.
221.
Testa, B. and P Jenner (1981). Inhibitors of
cytochrome P-450s and their mechanism of action.
DrugMetab. Rev. 12,
1-117.
222.
Waxman, D.J. and C. Walsh (1983). Cytochrome
P-450 isozyme 1 from phenobarbital-induced
rat liver: Purification, characterization, and